Equity Profile

RGEN

Repligen Corporation

Health CareLife Sciences Tools & Services$9.5B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Repligen Corporation (RGEN) operates in the health care sector, focusing on life sciences tools and services. The company plays a crucial role in bioprocessing, providing products that support the development and manufacturing of biologic drugs, which are increasingly important in modern medicine.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$0.46

Revenue

Revenue growth reflects the company's ability to expand its market share and meet demand in the life sciences sector.

$207M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, exceeding expectations by 25%. The stock reacted positively, gaining 6.26% the following day.

Management Promises & Guidance

Focus on expanding product offerings in bioprocessing.
Commitment to enhancing customer support and service.
Plans to invest in research and development for innovative solutions.

Expectations

Wall Street Expectations

Analysts expect Repligen to report solid earnings this quarter, with a consensus EPS of $0.46 and revenue of $207M. The market is keen to see if the company can maintain its growth trajectory.

Bull Case

If Repligen beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products, leading to a positive reassessment of its growth potential.

Bear Case

Conversely, if the company misses estimates or provides weak guidance, it may raise concerns about market demand and competitive pressures in the life sciences sector.

Key Metrics to Watch

EPS

$0.46

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$207M

Revenue growth reflects the company's ability to expand its market share and meet demand in the life sciences sector.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Repligen achieve an EPS of $0.46 or higher?

This figure is crucial as it sets the tone for investor confidence and reflects the company's operational efficiency.

What revenue growth can we expect compared to the consensus of $207M?

Revenue performance will indicate market demand for Repligen's products and its competitive position in the industry.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Repligen's growth potential, as recent trends in bioprocessing indicate a stronger demand than reflected in current estimates.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a trend of operational strength.

Recent industry reports indicate increasing investment in bioprocessing technologies, which may benefit Repligen.

Options pricing suggests a lower expected move, indicating that the market may not fully appreciate potential upside.

Key Risk

If Repligen reports revenue significantly above $207M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Repligen's ability to sustain growth in a competitive landscape, making these metrics critical.

Bull Confirmed If

An EPS of $0.46 or higher, coupled with revenue exceeding $207M, would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.41 or revenue falling short of $205M would raise significant concerns about market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting that traders expect some volatility but not a dramatic shift.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests the stock could rise around 3.95%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a decline, with historical data suggesting an average drop of around 4.72%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in bioprocessing.
2Any commentary on customer demand trends and market expansion.
3Insights into research and development initiatives.
4Details on cost management and operational efficiency.
5Management's outlook on competitive pressures in the life sciences sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$0.46

Revenue

Revenue growth reflects the company's ability to expand its market share and meet demand in the life sciences sector.

$207M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, exceeding expectations by 25%. The stock reacted positively, gaining 6.26% the following day.

Management Promises & Guidance

Focus on expanding product offerings in bioprocessing.
Commitment to enhancing customer support and service.
Plans to invest in research and development for innovative solutions.

Expectations

Wall Street Expectations

Analysts expect Repligen to report solid earnings this quarter, with a consensus EPS of $0.46 and revenue of $207M. The market is keen to see if the company can maintain its growth trajectory.

Bull Case

If Repligen beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products, leading to a positive reassessment of its growth potential.

Bear Case

Conversely, if the company misses estimates or provides weak guidance, it may raise concerns about market demand and competitive pressures in the life sciences sector.

Key Metrics to Watch

EPS

$0.46

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$207M

Revenue growth reflects the company's ability to expand its market share and meet demand in the life sciences sector.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Repligen achieve an EPS of $0.46 or higher?

This figure is crucial as it sets the tone for investor confidence and reflects the company's operational efficiency.

What revenue growth can we expect compared to the consensus of $207M?

Revenue performance will indicate market demand for Repligen's products and its competitive position in the industry.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Repligen's growth potential, as recent trends in bioprocessing indicate a stronger demand than reflected in current estimates.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a trend of operational strength.

Recent industry reports indicate increasing investment in bioprocessing technologies, which may benefit Repligen.

Options pricing suggests a lower expected move, indicating that the market may not fully appreciate potential upside.

Key Risk

If Repligen reports revenue significantly above $207M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Repligen's ability to sustain growth in a competitive landscape, making these metrics critical.

Bull Confirmed If

An EPS of $0.46 or higher, coupled with revenue exceeding $207M, would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.41 or revenue falling short of $205M would raise significant concerns about market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting that traders expect some volatility but not a dramatic shift.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests the stock could rise around 3.95%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a decline, with historical data suggesting an average drop of around 4.72%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in bioprocessing.
2Any commentary on customer demand trends and market expansion.
3Insights into research and development initiatives.
4Details on cost management and operational efficiency.
5Management's outlook on competitive pressures in the life sciences sector.